Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06878560
PHASE1/PHASE2

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

Sponsor: United Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, 10 GE Xenokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant.

Official title: EXPAND: A Prospective Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With End-stage Renal Disease (ESRD)

Key Details

Gender

All

Age Range

40 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2025-10-29

Completion Date

2075-10

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

BIOLOGICAL

10 GE Xenokidney

Porcine-derived kidney containing intentional genomic alterations for xenotransplantation

Locations (2)

Northwestern Memorial Hospital

Chicago, Illinois, United States

New York University Langone Health

New York, New York, United States